Physiomics PLC PARNTER study recruits first patient (0507M)
16 Septiembre 2021 - 8:44AM
UK Regulatory
TIDMPYC
RNS Number : 0507M
Physiomics PLC
16 September 2021
16 September 2021
Physiomics plc
("Physiomics") or ("the Company")
PARTNER study recruits first patient
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions is pleased to announce its PARTNER
study has recruited its first patient. The study, which received
formal Health Research Authority (HRA) ethics approval in December
2020 and started recruiting just this month, has been commissioned
to gather data for the further development of Physiomics'
personalised oncology dosing tool.
The PARTNER study is an observational clinical trial that will
be run by the Portsmouth Technology Trials Unit (PTTU), which is a
collaboration between Portsmouth Hospitals University NHS Trust
(PHU) and the University of Portsmouth, specialising in clinical
trials in new healthcare technologies. First announced in March
2020, the PARTNER study is funded by a 'Connect' award from
National Institute for Health Research (NIHR) Invention for
Innovation programme.
The title of the award project is "Further development of, and
evidence generation for a precision tool for optimising
chemotherapy dosing in advanced prostate cancer (NIHR201282)". The
award provides 100% reimbursement of project costs of up to
GBP150,000 over the duration of the project which was originally
scheduled to end in April 2021 but which has been delayed due to
the Covid pandemic (as announced on 10 May 2021). NIHR has now
formally agreed that the project will be extended until April 2022,
with no change in the total project costs.
In parallel with the UK-based PARTNER study, Physiomics plc is
engaged in a collaboration with US company TabulaRasa Healthcare
(TRHC), to integrate Physiomics' personalised dosing software into
TRHC's DoseMeRx(R) suite of personalised dosing solutions.
Dr Jim Millen, CEO of Physiomics, commented: "We're very excited
that the PARTNER trial is now underway despite all the challenges
presented by the current COVID pandemic. I'd like to take the
opportunity to thank the doctors, nurses and research team at PHU
and University of Portsmouth for their support so far, despite what
must have been a really difficult last twelve months. We look
forward to monitoring the recruitment going forwards and generating
some great data to support the further development of our
tool."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Limited (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
About the National Institute for Health Research (NIHR)
The mission of the National Institute for Health Research (NIHR)
is to improve the health and wealth of the nation through research.
We do this by:
-- Funding high quality, timely research that benefits the NHS, public health and social care;
-- Investing in world-class expertise, facilities and a skilled
delivery workforce to translate discoveries into improved
treatments and services;
-- Partnering with patients, service users, carers and
communities, improving the relevance, quality and impact of our
research;
-- Attracting, training and supporting the best researchers to
tackle complex health and social care challenges;
-- Collaborating with other public funders, charities and
industry to help shape a cohesive and globally competitive research
system;
-- Funding applied global health research and training to meet
the needs of the poorest people in low and middle income
countries.
NIHR is funded by the Department of Health and Social Care. Its
work in low and middle income countries is principally funded
through UK Aid from the UK government.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCLFMJTMTIBBTB
(END) Dow Jones Newswires
September 16, 2021 09:44 ET (13:44 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024